BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-501@pharmaconomics
DTSTAMP:20260707T015313Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TECX Phase 2 — TX45 (estimated date)
DESCRIPTION:Phase 2 trial results for TX45 in Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF) are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1681087/000119312526212069/tecx-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/501
URL:https://pharmaconomics.com/e/501
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TECX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR